Encoded Therapeutics raised $275 million in a Series F to push its lead gene therapy ETX101 into clinical trials for Dravet syndrome. The financing will also fund development work for a second program, ETX301, planned for a 2027 IND filing. The company is also enrolling young children in a registration-directed study and expanding into adolescents, with additional manufacturing scale-up underway rather than relying solely on contract production—an operational choice aimed at reducing throughput constraints for gene therapy assets.